EP2922827A4 - Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton - Google Patents

Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton

Info

Publication number
EP2922827A4
EP2922827A4 EP13857254.0A EP13857254A EP2922827A4 EP 2922827 A4 EP2922827 A4 EP 2922827A4 EP 13857254 A EP13857254 A EP 13857254A EP 2922827 A4 EP2922827 A4 EP 2922827A4
Authority
EP
European Patent Office
Prior art keywords
bruton
disease
treating
methods
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13857254.0A
Other languages
German (de)
English (en)
Other versions
EP2922827A2 (fr
Inventor
Tom Daniel
Kenichi Takeshita
Kenneth Foon
Jay Mei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Avilomics Research Inc
Original Assignee
Celgene Avilomics Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Avilomics Research Inc filed Critical Celgene Avilomics Research Inc
Publication of EP2922827A2 publication Critical patent/EP2922827A2/fr
Publication of EP2922827A4 publication Critical patent/EP2922827A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP13857254.0A 2012-11-20 2013-11-19 Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton Withdrawn EP2922827A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728701P 2012-11-20 2012-11-20
US201361870720P 2013-08-27 2013-08-27
PCT/US2013/070772 WO2014081712A2 (fr) 2012-11-20 2013-11-19 Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton

Publications (2)

Publication Number Publication Date
EP2922827A2 EP2922827A2 (fr) 2015-09-30
EP2922827A4 true EP2922827A4 (fr) 2016-06-08

Family

ID=50776662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13857254.0A Withdrawn EP2922827A4 (fr) 2012-11-20 2013-11-19 Méthodes de traitement d'une maladie ou d'un trouble associé à la tyrosine kinase de bruton

Country Status (3)

Country Link
EP (1) EP2922827A4 (fr)
TW (1) TW201427667A (fr)
WO (1) WO2014081712A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030720T2 (en) 2010-05-31 2017-06-28 Ono Pharmaceutical Co Purinone derivative as btk kinase inhibitor
KR20180034705A (ko) 2011-11-29 2018-04-04 오노 야꾸힝 고교 가부시키가이샤 퓨리논 유도체 염산염
CA2900012A1 (fr) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Inhibiteurs d'erk et leurs utilisations
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN105792846A (zh) * 2013-11-07 2016-07-20 豪夫迈·罗氏有限公司 抗cd20抗体与btk抑制剂的组合疗法
JP6528779B2 (ja) 2014-03-25 2019-06-12 小野薬品工業株式会社 びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
WO2016025561A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Formes et compositions d'un inhibiteur d'erk
JP6750613B2 (ja) 2015-04-09 2020-09-02 小野薬品工業株式会社 プリノン誘導体の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158571A1 (fr) * 2008-06-27 2009-12-30 Avila Therapeutics And Uses Thereof Composés hétéro-aryles et leurs utilisations
WO2011153514A2 (fr) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2013063401A1 (fr) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2055313E (pt) * 1998-11-09 2015-08-25 Biogen Idec Inc Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX336875B (es) * 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
US8703767B2 (en) * 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158571A1 (fr) * 2008-06-27 2009-12-30 Avila Therapeutics And Uses Thereof Composés hétéro-aryles et leurs utilisations
WO2011153514A2 (fr) * 2010-06-03 2011-12-08 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2013063401A1 (fr) * 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Méthodes de traitement d'une maladie ou d'une affection associée à la tyrosine-kinase btk (bruton's tyrosine kinase)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAN A BURGER ET AL: "The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients", 1 November 2012 (2012-11-01), pages 187, XP002736107, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper47509.html> *
RAJENDRA N DAMLE ET AL: "Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR)", 15 April 2013 (2013-04-15), pages 3531, XP002736105, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/3531.short> DOI: 10.1158/1538-7445.AM2013-3531 *

Also Published As

Publication number Publication date
WO2014081712A3 (fr) 2015-07-16
WO2014081712A2 (fr) 2014-05-30
TW201427667A (zh) 2014-07-16
EP2922827A2 (fr) 2015-09-30

Similar Documents

Publication Publication Date Title
EP2770830A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;une affection associée à la tyrosine-kinase btk (bruton&#39;s tyrosine kinase)
IL269511A (en) New therapeutic approaches to treat Parkinson&#39;s disease
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
IL266648B (en) A method for treating Parkinson&#39;s disease
EP2922827A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;un trouble associé à la tyrosine kinase de bruton
EP2925740A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
IL245042A0 (en) Treatment with proton tyrosine kinase inhibitors and immunotherapy
EP2809673A4 (fr) Molécules cycliques en tant qu&#39;inhibiteurs de tyrosine kinase de bruton
SG11201602421VA (en) Inhibitors of bruton&#39;s tyrosine kinase
EP2858500A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP2922546A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;un trouble associé à la tyrosine kinase de bruton
EP2844256A4 (fr) Traitement d&#39;une maladie neurale avec des inhibiteurs de tyrosine kinase
ZA201400012B (en) Inhibitors of bruton&#39;s tyrosine kinase
ZA201308397B (en) Inhibitors of bruton&#39;s tyrosine kinase
ZA201400739B (en) Inhibitors of bruton&#39;s tyrosine kinase
EP2833886A4 (fr) Quinoléines substituées en tant qu&#39;inhibiteurs de tyrosine kinases de bruton
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2680842A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;un état pathologique du système nerveux central
PL2959903T3 (pl) Lek do leczenia chorób oczu
ES2627541T8 (es) Métodos para tratar la enfermedad de Parkinson
EP2922826A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;un trouble associé à la tyrosine kinase de bruton
EP2814474A4 (fr) Procédés de traitement et de prévention de maladies et de troubles du système nerveux central
EP2906225A4 (fr) Procédés de traitement de la maladie de kennedy
EP2892538A4 (fr) Procédés de traitement d&#39;une maladie ou affection associée à la bruton tyrosine kinase
EP3113779A4 (fr) Méthodes de traitement d&#39;une maladie ou d&#39;un trouble de la tyrosine kinase de bruton

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150615

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20160511

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20171114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180327